P2-122Retrospective study to evaluate treatment outcomes of Pleural Mesothelioma treated in a tertiary care centre from India

Background: Malignant mesothelioma is a rare and insidious neoplasm with a poor prognosis. Rapid progression of the disease and no effective therapeutic approach results in a median survival time of less than 12 months.We evaluated the demographic pattern and outcomes of patients of Malignant pleural mesothelioma treated at our centre. Methods: MPM patients who were treated with different regimens at Tata Memorial Centre from July 2013 till September 2017 were analyzed. The primary objective was the overall survival (OS), secondary objectives were response rates, PFS. Descriptive statistics were summarised with median and range, survival outcomes were analysed with Kaplan-Meier method Results: A total of 46 patients were diagnosed as MPM. 27 patients who were treated with palliative intent were included in the analysis. The median age of patients was 59 years. The most common presenting complaints was chest pain (77.8%) followed by breathlessness (70.4%). One patient had paratesticular mass at presentation.19 (70.4%) patients were metastatic at the time of presentation. Pemetrexed and Carboplatin was the most common chemotherapeutic regimen in 1st line setting given to 21 (77.8%) patients. 5 (18.5%) patients received maintenance Pemetrexed. Median number of chemotherapy cycles in 1st line setting was 4 (Range-2 to 32 cycles).18 (66.6%) patients had response to first line chemotherapy.11 (40.7%) patients received second line chemotherapy. On 1st line chemotherapy, 5 patients had grade 3 hematological toxicities,1 patients had febrile neutropenia and 1 patient on maintenance bevacizumab developed bowel perforation. The median PFS and OS for was 9.7 months and 12.4 months respectively. The Epitheloid variant had highest median OS of 15 months. After a median follow up of 9.8 months, 18 (66.7%) died. Conclusion: Median overall survival for our patients who are treated with palliative intent is 12.4 months. Patients who received maintenance Pemetrexed seem to have better PFS.